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BRIEF ABSTRACT
The immediate impact of rapid glucose lowering induced by bariatric surgery on diabetic
retinopathy (DR) progression remains unclear. We present 3-year changes in the Best-
Corrected Visual Acuity and DR grade in a retrospective observational study of 32 morbidly
obese patients (64 eyes) who underwent Roux-en-Y-gastric bypass surgery. We found that
despite overall benefits in vision, there was an initial progression from no retinopathy to
background retinopathy in 18.9% and 21.7% at year 1 and 2 respectively. Patients with pre-
proliferative DR at baseline were at increased risk of developing sight-threatening DR. We
recommend that patients with diabetes undergoing bariatric surgery have a baseline visual
acuity, macular Optical Coherent Tomography and diabetic retinopathy grading from wide-
field digital imaging to identify those at risk of sight-threatening diabetic retinopathy.
Introduction
Bariatric surgery is recognised as an effective treatment for achieving significant weight loss
and in inducing significant and rapid improvement in glycaemic control with, in some cases,
remission of type 2 diabetes (T2D) [1]. The UK National Institute of Clinical Excellence
(NICE) has recommended bariatric surgery as a treatment option for obese patients with T2D
with a Body Mass Index of >35kg/m2 and/or who are refractory to other weight-loss
management options [2]. There are concerns regarding the acute impact of rapid glucose
lowering induced by bariatric surgery on diabetic retinopathy (DR) progression, with some
studies showing a paradoxical worsening of DR [3], no effect [4] or an improvement in DR
[5]. Rapid and marked reductions in HbA1c, as a result of improved glycaemic control
initiated during pregnancy or intensified insulin treatment, have previously been associated
with a transitory worsening of DR [6].
To observe the impact of bariatric surgery on Best-Corrected Visual Acuity (BCVA) and DR
grade, we present the results of a 3 year retrospective observational study of 32 morbidly
obese patients (64 eyes) with T2D following Roux-en-Y-gastric bypass (RYGB) surgery at
Derby Teaching Hospitals, a regional centre for bariatric surgery.
Methods All patients were registered with the Derbyshire Diabetic Retinopathy Screening
programme and had given their informed consent for anonymised data to be used in audit and
research. This consecutive series of 32 patients with T2D who underwent RYGB bariatric
surgery in a single tertiary bariatric centre, had data collected retrospectively from the DRSS
or diabetic retinopathy clinic notes at baseline, 12, 24 and 36 months post-surgery;
specifically the LogMAR (logarithmic Minimum Angle of Resolution) BCVA and English
Diabetic Eye Screening Programme grades of diabetic retinopathy based on 3, 50o digital
images. No diabetic retinopathy is termed R0, background diabetic retinopathy R1, pre-
proliferative diabetic retinopathy R2, and stable or active proliferative diabetic retinopathy
termed R3s or R3a respectively. The presence or absence of diabetic maculopathy is termed
M1 or M0 respectively. Descriptive analysis used the number of eyes and the un-paired ‘t’-
test (Graphpad) was performed to compare means of BCVA, using patient numbers, not eyes.
Results
At baseline (Figure 1), R0 was present in 47 eyes (73.4%), 13 (20.2%) had R1, 3 (4.8%) had
R2 and 1 (1.6%) had R3s. Of those with R0 at baseline, 9 (18.9%) had progressed to R1 at 12
months and 10 (21.7%) at both 24 and 36 months. Of those with R1 at baseline, 2 (15%) had
regressed to R0 at 12 months, 11 (52%) at 36 months, with none developing R2 or worse. All
eyes with R2 at baseline progressed to R3a within 2 years. At 36 months there was a net
regression of diabetic retinopathy in most eyes with R0 present in 48 eyes (75%), R1 in 12
(18.6%), and 4 (6.4%) with active or stable R3.
The mean LogMAR BCVA at baseline was 0.18 in patients with R0. Those who did not
develop any diabetic retinopathy had a significant improvement in mean BCVA when
compared to baseline, being 0.13 at 12 months and 0.04 at both 24 and 36 months (p>0.001).
Those with R0 at baseline who progressed to R1 at 12 months also had an initial
improvement in the mean BCVA, being 0.08 at 12 months and 0.09 at 24 months but had
deteriorated to 0.22 at 36 months which was significantly worse when compared to baseline
(p=0.001, Figure 2). In patients with diabetic maculopathy at baseline the mean BCVA was
0.39 and 0.16 in those with no maculopathy but the mean BCVA in maculopathy patients
improved so that there were no significant differences between groups at years 1,2 or 3
(figure 3).
Discussion
The beneficial effect of intensive glycaemic control on microvascular outcomes in the long
term is well described. Optimization of glycaemic control remains the cornerstone of diabetes
management and the prevention of microvascular complications such as DR. Our observation
is consistent with previous studies which have reported a greater risk of worsening of diabetic
retinopathy as a result of rapid intensification of glucose control. Importantly, our present
study employed a more sensitive assessment method of visual outcome by incorporating
BCVA assessment with graded retinal imaging to chart the progression of DR.
While progression of DR observed in this study may be a manifestation of an “early
worsening” phenomenon attributable to a large and rapid reduction in HbA1c, the long term
benefits of improved glycaemic control may have overcome any short-term negative impact
on DR outcomes as shown by a net regression to R0 and better mean BCVA at 3 years.
However, the progression from R2 at baseline to R3a indicates that more severe levels of
retinopathy at baseline may require closer observation and intervention. More recently, The
SUSTAIN-6 clinical trial programme evaluated the efficacy and safety of semaglutide, a
glucagon-like peptide-1 analogue, for the treatment of T2D. It reported that despite a
significant reduction in HbA1c and weight loss, semaglutide was associated with a significant
increase in the risk of DR complications vs placebo [7]. Post hoc analyses however revealed
that the majority of the effect of DR progression with semaglutide vs placebo in this study
may be attributed to the magnitude and rapidity of HbA1c reduction during the first 16 weeks 
of treatment in patients who had pre-existing DR and poor glycaemic control at baseline, and
who were treated with insulin [8]. This concept is not dissimilar to other conventional agents
which cause abrupt glycaemic improvement such as insulin which already have warnings in
their prescribing information about the potential association with temporary worsening of
DR. For example, in the insulin glargine clinical development programme, more frequent DR
progression was reported with insulin glargine vs NPH insulin in patients with T2D [9].
However, a subsequent 5‐year DR trial, employing a 7‐field Early Treatment Diabetic
Retinopathy Study fundus photographic assessment, showed no detrimental effect with
insulin glargine vs NPH on the long‐term progression of DR [10].
In summary, although we found overall benefits in vision and retinopathy grade following
bariatric surgery, our study showed that those who develop diabetic retinopathy or whose
diabetic retinopathy progresses following bariatric surgery are at increased risk of developing
sight-threatening diabetic retinopathy. Patients with R2 at baseline are specifically at risk of
DR progression. We would recommend all patients with diabetes undergoing bariatric
surgery have baseline visual acuity, macular Optical Coherent Tomography and grading of
diabetic retinopathy from wide-field digital images to identify those at risk of progression to
sight-threatening diabetic retinopathy. This group would require closer monitoring and
intervention for up to 3 years. A prospective observational study would clarify the risk of
development or progression of diabetic retinopathy following bariatric surgery in morbidly
obese patients with type 2 diabetes.
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Figure legends
Figure 1
The percentage of eyes with retinopathy grades following bariatric surgery showing a net
progression from R0 to R1 in years 1 and 2, with regression back to R0 by year 3. All R2
patients progressed to R3 by year 2. Abbreviations: PRE-OP, pre-operative; YR1, 1year post-
surgery; YR2, 2 years post-surgery; YR3, 3 years post-surgery; R0, no diabetic retinopathy;
R1, background diabetic retinopathy; R2, pre-proliferative diabetic retinopathy; R3, active or
stable proliferative diabetic retinopathy
Figure 2
The mean BCVA in those remaining at R0 was significantly improved compared to baseline
at 12*, 24# and 36# months. In those who progressed to R1, the mean BCVA was improved at
12# and 24# months from baseline but was significantly worse at 36# months (unpaired ‘t’-test
with 32 patients, not 64 eyes, * p= 0.007, # p= 0.0001). Abbreviations: LogMAR BCVA,
logarithmic minimum angle of resolution best-corrected visual acuity; R0, no diabetic
retinopathy; R1, background diabetic retinopathy.
Figure 3
At baseline the mean BCVA in patients with maculopathy was reduced compared to those
without maculopathy, but at all post-operative visits there was no significant difference
between those with or without maculopathy. Abbreviations: LogMAR BCVA, logarithmic
minimum angle of resolution best-corrected visual acuity; M0, no diabetic maculopathy; M1,
diabetic maculopathy.
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Figure 1. Changes in Diabetic Retinopathy Grades after
Bariatric Surgery
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